Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 studyMatthew S. Davids, Jennifer R. Brown, David C. Fisher et al.|The Lancet Oncology|2021Cited by 102
Venetoclax plus dose-adjusted R-EPOCH for Richter syndromeMatthew S. Davids, Jennifer R. Brown, Kerry A. Rogers et al.|Blood|2021Cited by 75
Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk DiseaseChristine E. Ryan, Matthew S. Davids, Benjamin L. Lampson et al.|Blood|2022Cited by 23
Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)Matthew S. Davids, Jennifer R. Brown, Benjamin L. Lampson et al.|Blood|2020Cited by 19
A multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for Richter’s syndrome.Matthew S. Davids, Philip A. Thompson, Kerry A. Rogers et al.|Journal of Clinical Oncology|2020Cited by 12